Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Apr 16, 2026
Reporting period
Not applicable
Filed with the SEC
Apr 29, 2026
10% ownerIndirect holdingOther
Context
Classification
other
Code P in the derivative table; not an open-market share purchase
Planned / mechanical clue
None found in footnotes
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0000947871-26-000481
Filed / recorded
Apr 29, 2026, 1:41 AM UTC
Added to OQRO
Oct 8, 2026, 2:37 AM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Traws Pharma, Inc.
Issuer CIK
1130598
Ticker
TRAW
Reporting person
ORBIMED ADVISORS LLC
Relationship
10% owner
Security
Series C Warrants (right to buy)
Table
Derivative (Table II)
Transaction date
Apr 16, 2026
Transaction code
P
Shares / units
1,793,187
Acquired / disposed
Acquired (A)
Shares owned after
1,793,187
Ownership form
Indirect — See Footnote
Amendment
No
Footnotes from the filing
On April 15, 2026, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain investors (the "Investors"), including the Reporting Persons. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Persons in a private placement which closed on April 16, 2026 (the "Closing Date") Series A warrants, Series B warrants, and Series C warrants (collectively, the "Warrants") to purchase up to an aggregate of 2,988,645 shares. The price per Pre-Funded Warrant is $1.673.
The Warrants are exercisable pursuant to the conditions described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on April 15, 2026.
These securities are held of record by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VIII. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
“On July 29, 2026, Traws Pharma, Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the closing bid price for the Company’s common stock was below $1.00 per share for at least 30 consecutive business days, the Company is not currently in compliance with the minimum bid price requirement for…”
